Tamsulosin Hydrochloride
Product Images NDC 68071-2197

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 68071-2197). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2197 03 A96)

This is a medication product label for Tamsulosin HCI 0.4mg capsules. The label provides information on the manufacturer of the medication, its lot number, and expiration date. It also includes warnings, dosage instructions, and details on the packaging.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

This appears to be a figure or a graph with the title "Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose Administration of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted and Fed Conditions". It shows the concentration of the drug in the blood over time (hours) after taking a single dose of the drug in both fasted and fed conditions. Without the visual aid, it is impossible to provide a more detailed description of the results.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

This is a figure showing the mean change from baseline in total AUA Symptom Score in Study 1. The X-axis shows the duration of treatment in weeks and the Y-axis represents the mean change from baseline. There are two treatments being compared: treatment with -OO-0-08mg_~A= A -A04my_ O30 and treatment with placebo. There are different time points along with the study, represented on the X-axis, which range from 0 to 13 weeks. The total number of participants in the study is also shown for each time point.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

The text describes a figure showing the mean increase in peak urine flow rate in L/sec in Study 1. The figure indicates the treatment given, which includes various dosages of mg and a placebo. The study involved a total of 5 groups, with different sample sizes, and lasted for different durations in weeks.*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

FDA Label Image

Chemical Structure (Tamsulosin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.